📈 Economy · Next Week

Bristol-Myers Squibb (NYSE: BMY) beats Q2 2026 adjusted Non-GAAP EPS consensus of approx. $1.65 per share (July 30, 2026; confirmed by BMS press release)

Hit ✦ AI-generated prediction Published on 27. July 2026 · Predicted for 30. July 2026 · Based on: Historical Cycle

Probability

60%

BMS reports on July 30, 2026. Non-GAAP EPS consensus estimated at approximately $1.65 (extrapolated from Q1 2026 result and core product growth trajectory: Eliquis, Opdivo, Breyanzi). BMS has beaten EPS consensus for four consecutive quarters. Growing oncology pipeline (Opdualag, Camzyos, Breyanzi) offsets the fading Revlimid exclusivity tailwind. No Polymarket market; own estimate 60% (discount applied for consensus uncertainty).

Data basis for this prediction

BMS Q2 2026 Earnings Date: 30. Juli 2026 (BMS Investor Relations, 27.07.2026)
BMS: 4 aufeinanderfolgende EPS-Beats (Referenzwert Analystenberichte)
Breyanzi Q1 2026 Umsatz: stark wachsendes CAR-T-Segment (BMS IR)

Note: This is an AI-generated statistical forecast for entertainment and information purposes. It does not constitute investment advice or a recommendation to buy or sell any financial instrument.

Verdict: Hit

BMS meldete am 30. Juli 2026 einen Non-GAAP-EPS von 2,04 USD – weit über dem Konsens von ca. 1,59–1,61 USD (und damit erst recht über der in der Vorhersage angenommenen Konsensschätzung von ~1,65 USD). Das entspricht einem Beat von rund +0,43 USD bzw. ~27 %. Treiber waren das Wachstumsportfolio (+14 % ex-FX auf 7,6 Mrd. USD), insbesondere Eliquis und Opdivo. Der Jahresausblick für Non-GAAP-EPS wurde daraufhin von 6,05–6,35 USD auf 6,75–7,00 USD angehoben. Quellen: BMS-Pressemitteilung (news.bms.com), Investing.com, Yahoo Finance/Zacks.

Related Predictions

📈 Economy ✦ AI

S&P 500 (^GSPC) closes above 7,450 points on 30 September 2026 (confirmed by NYSE closing price or Bloomberg by 30 September 2026)

The S&P 500 closed at 7,636.36 on 9 September 2026. Falling below 7,450 by month-end would require a 2.4% decline. Headwinds: Fed rate hike of 25bp on 16 September (CentralBank.Watch: 59% probability), August PPI above expectations (+5.4% YoY), Iran-Gulf risk premium. Stabilizing factors: hike largely priced in (Polymarket: 93% for zero 2026 cuts), Q2 earnings solid, no recession signals. Historically, a single 25bp September hike rarely causes a monthly decline above 2.5%.

73%

Next Month · Predicted for 30. Sep 2026

📈 Economy ✦ AI

US Federal Reserve raises the Federal Funds target range by 25 basis points on 16 September 2026 (FOMC decision)

Polymarket shows a 53% probability for a 25 basis point hike as of September 10, 2026. US Core CPI August 2026 (release September 11) is expected by market consensus to be above 3.0% YoY. The ECB raised its deposit rate by 25 bps to 2.50% on September 10, 2026 – an inflation-fighting signal that provides cover for the Fed. Against a hike: a mild slowdown in US industrial output. CME FedWatch also shows ~53% probability for a hike.

53%

Next Week · Predicted for 16. Sep 2026

📈 Economy ✦ AI

DAX 40 (XETRA) closes above 26,000 points on 30 September 2026 (confirmed by XETRA closing price or Bloomberg by 30 September 2026)

The DAX closed at 25,562 points on September 9, 2026. A gain of +1.7% is required by month-end. Headwinds: ECB rate hike to 2.50% (September 10), 53% FOMC hike probability (September 16), persistently high oil prices (~$101/barrel Brent) weigh on energy-intensive DAX heavyweights. Tailwinds: strong SAP cloud growth expected, robust US demand, EUR/USD at 1.1644 benefits exporters. Implied 30-day volatility (VDAX): ~16%, corresponding to a σ range of roughly ±5.5% by month-end — the 26,000 level falls within the central distribution.

48%

Next Month · Predicted for 30. Sep 2026